In the 1st 9 months of 'twenty four, we purchased for cancellation a little over 1,000,000 subordinate voting shares, principally under our normal course issuer bid at a cost of $1,100,000,000 or US1113 dollars per share, of which 159,000 subordinate,000 shares at a cost of 181,000,000 were completed in the Q3 of 2024. At September 30, 2024, our excess of fair value over carrying value of our investments in the non insurance associates and market traded consolidated non insurance subsidiaries was $1,900,000,000 compared to the $1,000,000,000 at December 31, 2023. That pretax excess of $1,900,000,000 or $87 per share is not reflected in our book value per share, but is regularly reviewed by management as an indicator of the underlying investments performances. And included in that $1,900,000,000 is approximately $366,000,000 gain anticipated to be recognized by the company in the Q4 of 2024 relating to our sale of Stelco's common shares. The company's total debt to total capital ratio excluding our non insurance companies increased modestly to 24.2 at September 30, 2024 compared to 23.1 at December 31, 23, reflecting increase in total debt that was offset by our increased shareholder equity, principally reflecting the strong net earnings in the quarter in the 2024 9 months, reduced by purchases of our Sabonet boarding shares for cancellation I mentioned previously.